XBI
State Street SPDR S&P Biotech ETF
SPDR S&P Biotech ETF seeks to replicate the performance of the S&P Biotechnology Select Industry Index, an equal-weighed index. The Index tracks all the US common stocks listed on the NYSE, Ame
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 7.6 B
ASSETS UNDER MGMT
35 bp
EXPENSES
Fund Basics
| Inception date | Jan 31, 2006 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Quarterly |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| REVOLUTION MEDICINES, INC. | 1.7 % |
| TRAVERE THERAPEUTICS, INC. | 1.7 % |
| TG THERAPEUTICS INC | 1.6 % |
| ALKERMES PLC | 1.6 % |
| ARROWHEAD PHARMACEUTICALS, INC. | 1.5 % |
| NEUROCRINE BIOSCIENCES INC | 1.4 % |
| MADRIGAL PHARMACEUTICALS, INC. | 1.4 % |
| EXELIXIS INC | 1.4 % |
| KRYSTAL BIOTECH, INC. | 1.4 % |
| CYTOKINETICS INC | 1.4 % |
Constituent Breakdown
| Number of holdings | 136 |
| Herfindahl-Hirschman Index | 98 |
| Wgt avg mkt cap (mns) | $19,132 |
| Large cap (>$10bn) | 28.6% |
| Mid cap ($2-10bn) | 40.3% |
| Small cap (<$2bn) | 25.5% |
| Developed mkts. | 96.0% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 91.2 % |
 |
IRELAND | 1.7 % |
 |
BRITAIN | 1.2 % |
 |
SWITZERLAND | 1.1 % |
 |
NETHERLANDS | 0.6 % |
Historical Performance
Standardized Performance (as of 04/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 7.7% | 58.3% | 24.6% | 17.9% | -0.8% | 9.3% | 11.1% | 10.8% |
| Dividend Yield | 0.0% | 0.6% | 0.3% | 0.2% | 0.1% | 0.2% | 0.3% | 0.3% |
| Total Returns | 7.7% | 58.9% | 24.9% | 18.1% | -0.7% | 9.5% | 11.4% | 11.1% | Ann. Volatility | 29.6% | 26.0% | 26.4% | 27.0% | 32.1% | 32.1% | 30.7% | 30.6% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.12 | 29% |
| MSCI EAFE | 0.92 | 27% |
| MSCI Emg Mkts | 0.62 | 19% |
Liquidity Measures
| Avg. volume (000) | 7,916 |
| ADV traded (mns) | $1,004 |
| Turnover | 13.2% |
| Avg. Bid/Ask (% of price) | 0.01% |
Technical Indicators
| 30d moving avg. (EMA) | $132.50 |
| Relative strength (RSI) | 50 |
| MACD/Signal | 0.94/1.34 |
| Bollinger Bands (Upper/Lower) | $138.77/$129.08 |
| Short interest (% of AUM) | 112.5% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. XBI |
Expenses vs. XBI |
ALTAR Score™ vs. XBI |
|---|---|---|---|---|
| IBB | iShares Biotechnology ETF | 41.9% | +10 bp | -0.5% |
| BBP | Virtus LifeSci Biotech Products ETF | 41.8% | +44 bp | -3.8% |
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | 35.2% | +44 bp | +0.0% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 34.1% | -16 bp | +0.4% |
| WDNA | WisdomTree BioRevolution Fund | 34.1% | +10 bp | -3.1% |
| SBIO | ALPS Medical Breakthroughs ETF | 27.6% | +15 bp | +0.0% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 26.1% | +25 bp | +7.8% |
| HELX | Franklin Genomic Advancements ETF | 23.2% | +15 bp | -1.0% |
| CANC | Tema Oncology ETF | 23.0% | +40 bp | -2.0% |
| PBE | Invesco Biotechnology & Genome ETF | 21.7% | +23 bp | +3.2% |
Risk and Returns: XBI vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/20/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.0%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,346 funds in the US Equity category with an average
ALTAR Score™ of 5.5% and a standard deviation
of 2.1%. XBI's ALTAR Score™ is approximately -2.7 standard
deviations above the category average. This places XBI in the 1st percentile
among funds in the category.
Sell-Side Consensus
$165.5
PRICE TARGET
+30.5%
UPSIDE